# The Relation Between von Willebrand Factor Plasma Concentration and Ultrasonograohic Doppler Findings in Pregnancies Complicated by Hypertensive Disorders

Zaman Farhan Mohammed <sup>1</sup>, Israa Hashim Abid-Alkareem <sup>2</sup> <sup>1</sup> M. B. Ch. B. Tikrit Health Directorate, Iraq <sup>2</sup> M.B.Ch.B, F.I.C.O.G, College of Medicine, Tikrit University, Iraq

#### Abstract

**Background:** Hypertensive disorder of pregnancy is one of the most common complications in pregnancy forming a triad together with hemorrhage and infection. It affects about 10% of pregnancies and contributes for a significant maternal and perinatal mortality.

**Aim:** The aim of this study was to evaluate the relationship between maternal plasma VWF level and fetal Doppler flow measurements in pregnancies complicated by hypertensive disorders

**Patients and methods:** A case-control study was conducted in Tikrit city from March to September 2019. From a total of 100 enrolled pregnant women, 65 were eligible for the final analyses. 35 were excluded because they did not meet the inclusion criteria. The 65 women were placed into the following groups: pregnant women with chronic hypertension (n = 25), those with gestational hypertension (n = 20), and those with preeclampsia (n = 20). These pregnant women were included in the study when attended Salah Al-Din General Hospital, Labor room. A control group of 22 healthy normotensive pregnant females was also included. The Doppler flow measurements of uterine arteries, umbilical artery, and middle cerebral artery were obtained by ultrasound (Philips 6Hd 11EX) using a convex probe (frequency 3.5–5 MHz). Measurements were taken when the fetus was not moving and did not have any breathing movements. Venous blood was collected for to measurement vWf by ELISA

**Results:** The study demonstrated that the highest mean of VWF was observed in pregnant women with Preeclampsia  $(5.71\pm1.14 \text{ pg/ml})$  followed by gestational hypertension group  $(4.33\pm0.60 \text{ pg/ml})$  and chronic hypertension group  $(3.29\pm0.55 \text{ pg/ml})$  and the lowest mean was within the control group  $(1.66\pm0.41 \text{ pg/ml})$ respectively (P. value <0.01). The study found increased vWf plasma concentrations in preeclamptic patients was associated with abnormal Doppler finding with no significant relation between gestational age of women with preeclamptic and abnormal Doppler finding

**Conclusions:** Increased vWf plasma concentration corresponds to ultrasonographic features of placental insufficiency in women with preeclampsia. This relationship may confirm severity of endothelial damage in preeclamptic patients. Widely available and relatively low-cost Doppler flow measurements may be useful for selecting women at higher risk of developing cardiovascular diseases.

Keywords: Von Willebrand; Doppler Findings; Pregnancy; Hypertensive Disorders; Preeclampsia

## Introduction

Hypertensive disorder of pregnancy is one of the most common complications in pregnancy forming a triad together with hemorrhage and infection. It affects about 10% of pregnancies and contributes for a significant maternal and perinatal mortality <sup>(1)</sup>. The World Health Organization (WHO) reported that 14.0% of global maternal deaths are attributed to hypertensive disorders of pregnancy <sup>(2)</sup>. Hypertension in pregnancy is defined as a systolic of 140 mm Hg or greater or a diastolic of 90 mm Hg or greater. Blood pressure should be taken in the upper arm with the patient seated using an appropriately sized cuff<sup>(3)</sup>. Hypertension in pregnancy is said to occur when the systolic blood pressure is  $\geq$ 140 mmHg and diastolic blood pressure is  $\geq$ 90 mmHg on at least two occasions, six hours apart. Hypertensive disorder of pregnancy encompasses gestational hypertension in pregnancy (hypertension without proteinuria), pre-eclampsia (hypertension with proteinuria) and eclampsia (pre-eclampsia with convulsions) <sup>(4)</sup>. Studies have attempted to explain the pathophysiology of hypertension in pregnancy; however, a consensus is lacking <sup>(5,6)</sup>. Recent evidence suggests that impaired placental vascularization is a major factor responsible for gestational hypertension development; however, the etiology is probably multifactorial. It has been suggested that impaired cytotrophoblast proliferation and migration are present, as is cell differentiation to endothelial cells in uterine arteries, and as a result there is impaired trophoblast invasion to placental blood vessels <sup>(7,8)</sup>. Scientists agree about the 2-stage model of preeclampsia development. The first stage begins just after trophoblast-impaired implantation that causes hypoxia. In this stage, impaired uterine artery may be observed in Doppler flows<sup>(9)</sup>. The second stage, when patients typically develop clinical symptoms, begins mostly after the 20<sup>th</sup> week of gestation and is caused by placental factors released into maternal blood<sup>(50)</sup>. As a result, systemic inflammation begins to damage endothelium in many organs, which is followed by typical preeclampsia symptoms <sup>(10)</sup>. However, the potential mechanisms of these changes have not been decisively explored. Von Willebrand factor (VWF) connects platelets with endothelial cells, collagens, and is responsible for the correct platelet-adhesion process <sup>(11,12)</sup>. The aim of this study to evaluate the relationship between maternal plasma VWF level and fetal Doppler flow measurements in pregnancies complicated by hypertensive disorders

## **Patients and methods**

A case-control study was conducted in Tikrit city in Salah Al din general hospital from first of March 2019 and to end of September 2019. From a total of 100 enrolled pregnant women, 65 were eligible for the final analyses. 35 were excluded because they did not meet the inclusion criteria. The 65 women were placed into the following groups: pregnant women with chronic hypertension (n = 25), those with gestational hypertension (n = 20), and those with preeclampsia (n = 20), patients were defined and divided according to he National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. A control group of 22 healthy normotensive pregnant females was also included. All comparison groups were matched for mother's age, parity, and gestational age at the time of enrollment and blood collection.

## **Inclusion criteria**

- 1. Singleton pregnant women with chronic hypertension.
- 2. Singleton pregnant with gestational hypertension.
- 3. Singleton pregnant with preeclampsia.
- 4. Age: 15-45 year
- 5. Parity: 1-7.

## **Exclusion criteria**

- 1. Multiple gestations.
- 2. Fetal structural/genetic anomalies.
- 3. Maternal renal disease.
- 4. Metabolic disease.
- 5. Inflammatory disease.
- 6. Autoimmune disease, and other comorbidities associated with endothelial damage.

## Methods

Hypertensive disorders were defined according to classification of The National High Blood pressure Education program Working group on High Blood pressure in pregnancy. Twenty-four-hour autamatic blood pressure monitoring was performed Blood pressure readings were taken at 30minute intervals. For patients who was admitted to the hospital and two readings of blood pressure was taken for patients who was not admitted to the hospital and diagnosed as hypertensive disorders depend on history and examination and blood pressure readings that record on antenatal card in each antenatal visit. Measurement of Bp done by sphygmomanometer in sitting position, with cuff size appropriate to patients arm circumference was used, and to eliminate possible stressor for the patients, the visual preview of blood pressure measurement was removed.

Three ml of blood was collected by vein puncture, blood samples were placed into sterile test tubes and left for 30 minutes at 37 °C then were centrifuged at 3000 rpm for 15 minutes then the clot was removed and the obtained sera were then aspirated using automatic micropipette and transferred into clean test tubes and stored in deep freeze at -20°C for determination of vWF by using ELISA technique

Every woman had ultrasound examination with Doppler flow measurements of uterine arteries, umbilical vessels, and fetal middle cerebral artery, simultaneously with recruitment into study and blood sample collection. Doppler done by 2 radiologists and they confirmed the same results. The Doppler flow measurements of uterine arteries, umbilical artery, and middle cerebral artery were obtained by ultrasound (Philips 6Hd 11EX)using a convex probe (frequency 3.5–5 MHz). Measurements were taken when the fetus was not moving and did not have any breathing movements.

## Results

As shown in Table 1. There was no significant difference between studied cases and the control group regarding patient age and gestational age at sampling and parity (P>0.05) while there was a significant difference between studied cases and the control group regarding systolic and diastolic blood pressure (P <0.05).

14	Chronic Costational			
Parameters (Mean±SD)	Chronic hypertension	Gestational hypertension	Pre-eclampsia	Control group
No.	25	20	20	22
Maternal age (yeas)	32.5±4.2	30.1±4.1	32.2±5.9	32.2±6.2
Gestational age	33.4±7.5	36.8±4.1	34.1±3.2	35.4±6.6
Parity, median (Range)	2 (1–7)	2 (1-4)	1 (1-6)	2 (1-6)
Mean 24 h SBP, mm Hg	128.7±11.5 *	133.4±13.1*	148.6±14.3*	110.8±7.4
Mean 24 h DBP, mm Hg	83.5±6.9*	84.7±9.9*	96.6±12.9*	69.4±8.3
Maximal SBP, mm Hg	167±24.1*	153.9±18.2*	177.9±24.1*	119.0±10.2
Maximal DBP, mm Hg	109.1±22.7*	105.8±17.0*	118.8±12.8*	74.7±13.3

## Table 1: Clinical characteristics of studied women

\* Statistically significant differences (p < 0.05) between studies and control group.

SBP, systolic blood pressure; DBP, diastolic blood pressure.

No statistically significant differences existed between groups in (T. Test p = NS).

The study demonstrated that VWF mean was significantly elevated in pregnant women with chronic hypertension as compared with the control group ( $3.29\pm0.55$  and  $1.66\pm0.41$  pg/ml) respectively (P. value <0.01)

The study demonstrated that the highest mean of VWF was observed in pregnant women with Preeclampsia followed by gestational hypertension group and chronic hypertension group and the lowest mean was within the control group (P. value <0.001), as shown Table 3.

VWF (pg/ml)	Chronic hypertension	Gestational hypertension	Pre- eclampsia	Control group	ANOVA	P. value
Ν	25	20	20	22		
Mean	3.29	4.33	5.71	1.66	118.4	0.0001
SD.	0.55	0.60	1.14	0.41		

## Table 3: Comparison of the von Willebrand factor among the studied groups.

In Table 4, the results are provided for Doppler flow measurements in study and control groups. **Table 4: Doppler ultrasound results in each patient group** 

	Chronic hypertension	Gestational hypertension	Pre-eclampsia	Control group
PI-UA	1.2±0.27*	1.09±0.28	1.33±0.43*	0.71±0.17

$(\text{mean} \pm \text{SD})$				
PI-MCA (mean ± SD)	1.59±0.43	1.59±0.33	1.42±0.39*	1.81±0.51
CUR (mean ± SD)	1.49±0.54*	1.61±0.71*	1.29±0.55*	2.31±0.55
PI-RtUtA (mean ± SD)	1.11±0.5	1.21±0.83*	1.35±0.43*	0.44±0.21
PI-LtUtA (mean ± SD)	2.16±1.22*	0.91±0.55	1.71±0.65*	0.74±0.17
UAS (median; minimum – maximum)	2 (0-4)	0 (0-4)	3 (0-4)	0 (0–0)

\* Statistically significant differences compared with those of the control group (p < 0.05; Mann-Whitney test). PI-UA, umbilical artery pulsatility index; PI-MCA, middle cerebral artery pulsatility index; CUR, cerebroumbilical ratio; PI-RtUtA, right uterine artery pulsatility index; PI-LtUtA, left uterine artery pulsatility index; UAS, uterine artery score.

#### 3.4. Relation of von Willebrand factor and Doppler finding in women with preeclampsia

The study found increased vWf plasma concentrations in preeclamptic patients was associated with abnormal Doppler finding (Table 5).

	Table 3.7: Relation of von	Willebrand factor and Do	oppler finding	in women with preeclampsia
--	----------------------------	--------------------------	----------------	----------------------------

VWF (pg/ml)	Normal Doppler finding	Abnormal Doppler finding
Ν	7	13
Mean	3.96	6.41
SD.	0.59	1.21

P. value: 0.001

## Discussion

The study demonstrated that the highest mean of VWF was observed in pregnant women with Preeclampsia followed by gestational hypertension group and chronic hypertension group and the lowest mean was within the control group (P. value <0.001), as shown Table 3. More recent studies have confirmed that in hypertension, vWf deposition in placental vessel walls may lead to their hyperplasia, impaired endothelial regeneration, and limited angiogenesis <sup>(7,8,9)</sup>. All these changes may lead to increased vessel resistance in Doppler ultrasound measurements. Soares et al (10) evaluated women with type 2 diabetes using ultrasonography Doppler for assessment of carotid intima-media thickness. Elevated vWf plasma concentration was found only in patients with moderate macrovascular disease ( $\geq 1$  mm and presence of plaque and stenosis) but was not detected in women without or with mild macrovascular disease. Molvarec et al <sup>(11)</sup> confirmed a correlation between increased vWf and soluble fms-like tyrosine kinase-1 (sFlt-1) plasma concentration in preeclamptic patients. Another study revealed that in late-onset preeclampsia, an imbalance existed in circulating angiogenic and anti-angiogenic factors already present at 8-10 weeks of pregnancy. Decreased PIGF plasma concentration, increased sFlt-1 plasma concentration, and increased sFlt-1/PIGF ratio were observed in these patients. Moreover, abnormal first trimester uterine arteries were found on ultrasound Doppler, and placental insufficiency was confirmed in histopathology after delivery <sup>(12)</sup>. It is highly probable that sFlt-1 and vWf play a key role in the abnormal placentation, which is followed by symptoms of preeclampsia. It is well known that higher plasma concentrations of vWf are associated with hypertension and progression of cardiovascular disease <sup>(13)</sup>, including stroke, myocardial infarction, and venous thrombosis <sup>(14)</sup>. Furthermore, infactors for the development of microvascular complications in patients with diabetes mellitus <sup>(15)</sup>. The multimeric vWf is proteolytically regulated by the ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13). The ADAMTS13 is a metalloprotease enzyme that splits large, thrombogenic vWf multimers, decreasing their activity <sup>(16)</sup>. The importance of ADAMTS13 in supporting the balance of vWf multimeric size is well presented by its role in some hematologic diseases, for instance, idiopathic thrombotic thrombocytopenic purpura and some cases of von Willebrand disease. Many reports in the current literature demonstrate the association between high vWf plasma concentrations and/or low ADAMTS13 plasma levels with increased risk of thrombotic diseases <sup>(17-22)</sup>. Based on these studies, vWf may be a promising target in the prevention and eventually treatment of thrombotic diseases, and recombinant ADAMTS13 could be a novel therapeutic agent for use in such disorders <sup>(23)</sup>. Furthermore, some experimental animal models of ischemic stroke and myocardial infarction supported vWf as a potential therapeutic target (24). The Doppler flow measurements for evaluating placental efficiency and eventually the assessment of vWf plasma concentration in preeclamptic women may identify the patients at much higher risk of cardiovascular diseases in the future and may qualify them for such prevention and eventually therapy. vWf is synthesized by endothelial cells and megakaryocytes. Significantly higher plasma vWf concentrations have been found in pregnancies complicated by gestational hypertension and preeclampsia compared with healthy pregnancies <sup>(8)</sup>. Several studies have found a correlation between abnormal uterine artery Doppler flow and preeclampsia development. In 2008, Brodszki et al (27) reported that bilateral notch sign in uterine arteries and elevated resistance in maternal-fetal circulation corresponds to more advanced endothelial damage. Moreover, it has conclusively been shown that increased vascular resistance in the course of preeclampsia is followed by abnormal middle cerebral and umbilical artery flow, especially in intrauterine growth-restricted fetuses <sup>(11)</sup>.

#### Conclusions

- 1- The highest mean of VWF was observed in pregnant women with Pre-eclampsia followed by gestational hypertension group and chronic hypertension group and the lowest mean was within the control group
- 2- This relationship may confirm severity of endothelial damage in preeclamptic patients.
- 3- Widely available and relatively low-cost Doppler flow measurements may be useful for selecting women at higher risk of developing cardiovascular diseases.

## Recommendations

1- Future investigations need with large population studies regarding the relation of vWf with hypertension pregnancy.

1- Further studies required for evaluate the relation of vWf level with pre-eclapmsia in first months of pregnancy.

#### References

- Sultana S, Yasmin T, Mollah MN, Roy SK, Hossain MS, Al-Amin A. Duplex color doppler study of uterine artery in early diagnosis of preeclampsia. Bangladesh Medical Research Council Bulletin. 2019 Jun 15;45(1):34-40.
- 2. Chen X, Zhou J, Xu L, Chen L, Mao P, Yang X. Serological ferritin, 100A12, procalcitonin and APACHEII score in prediction the prognosis of acute respiratory distress syndrome. Pteridines. 2019 Feb 1;30(1):165-70.
- 3. Elnabtity AM, Selim MF. Norepinephrine versus ephedrine to maintain arterial blood pressure during spinal anesthesia for cesarean delivery: A prospective double-blinded trial. Anesthesia, essays and researches. 2018 Jan;12(1):92.
- 4. Marin JR, Abo AM, Arroyo AC, Doniger SJ, Fischer JW, Rempell R, Gary B, Holmes JF, Kessler DO, Lam SH, Levine MC. Pediatric emergency medicine point-of-care ultrasound: summary of the evidence. Critical ultrasound journal. 2016 Dec;8(1):16.
- 5. Panchal S, Nagori C. Color Doppler in Obstetrics & Gynecology. Jaypee Brothers, Medical Publishers Pvt. Limited; 2019 Mar 31.
- 6. Fadal Allah SM. *Study of Umbilical Arteries in Diabetic Mothers using Doppler* (Doctoral dissertation, Sudan University of Science & Technology).
- 7. Bartoli CR, Zhang DM, Hennessy-Strahs S, Kang J, Restle DJ, Bermudez C, Atluri P, Acker MA. Clinical and in vitro evidence that left ventricular assist device–induced von Willebrand factor degradation alters angiogenesis. Circulation: Heart Failure. 2018 Sep;11(9):e004638.

- 8. Randi AM, Laffan MA, Starke RD: Von Willebrand factor, angiodysplasia and angiogenesis. Mediterr J Hematol Infect Dis 2013; 5:e2013060.
- 9. Qin F, Impeduglia T, Schaffer P, Dardik H: Overexpression of von Willebrand factor is an independent risk factor for pathogenesis of intimal hyperplasia: preliminary studies. J Vasc Surg 2003; 37: 433–439.
- Soares AL, Kazmi RS, Borges MA, Rosario PW, Fernandes AP, Sousa MO, Lwaleed BA, Carvalho MG: Elevated plasma factor VIII and von Willebrand factor in women with type 2 diabetes: inflammatory reaction, endothelial perturbation or else?. Blood Coagul Fibrinolysis 2011; 22: 600– 605.
- 11. Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigó J Jr: Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens Res 2010; 33: 892–898.
- 12. Triunfo S, Crovetto F, Crispi F, Rodriguez- Sureda V, Dominguez C, Nadal A, Peguero A, Gratacos E, Figueras F: Association of first-trimester angiogenic factors with placental histological findings in late-onset preeclampsia. Placenta 2016; 42: 44–50.
- 13. Szpera-Gozdziewicz A, Gozdziewicz T, Boruczkowski M, Dworacki G, Breborowicz GH. Relationship between the von Willebrand Factor Plasma Concentration and Ultrasonographic Doppler Findings in Pregnancies Complicated by Hypertensive Disorders: A Pilot Study. Gynecologic and obstetric investigation. 2018;83(3):252-8.
- 14. Xiang Y, Hwa J: Regulation of VWF expression, and secretion in health and disease. Curr Opin Hematol 2016; 23: 288–293.
- 15. Saboor M, Moinuddin, Ajmal M, Ilyas S: Functional status of vascular endothelium in diabetes mellitus. J Ayub Med Coll Abbottabad 2014; 26: 239–243.
- 16. Levy GG, Motto DG, Ginsburg D: ADAMTS13 turns 3. Blood 2005; 106: 11-17.
- 17. Miura M, Kaikita K, Matsukawa M, Soejima K, Fuchigami S, Miyazaki Y, Ono T, Uemura T, Tsujita K, Hokimoto S, Sumida H, Sugiyama S, Matsui K, Yamabe H, Ogawa H: Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease. Thromb Haemost 2010; 103: 623–629.
- 18. Bongers TN, de Bruijne EL, Dippel DW, de Jong AJ, Deckers JW, Poldermans D, de Maat MP, Leebeek FW: Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis 2009; 207: 250–254.
- 19. Gombos T, Makó V, Cervenak L, et al: Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure. Thromb Haemost 2009; 102: 573–580.
- 20. Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM: ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 138: 534–540.
- 21. Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR: ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 2007; 109: 1998–2000.
- 22. Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gomez Garcia EB, Dippel DW, Leebeek FW: High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006; 37: 2672–2677.
- 23. Andersson HM, Siegerink B, Luken BM, Crawley JT, Algra A, Lane DA, Rosendaal FR: High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood 2012; 119: 1555–1560.
- 24. Sonneveld MA, de Maat MP, Portegies ML, Kavousi M, Hofman A, Turecek PL, Rottensteiner H, Scheiflinger F, Koudstaal PJ, Ikram MA, Leebeek FW: Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood 2015; 126: 2739–2746.